<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747639</url>
  </required_header>
  <id_info>
    <org_study_id>HB-RCT2-2015</org_study_id>
    <nct_id>NCT04747639</nct_id>
  </id_info>
  <brief_title>Glycemic Response to Two Doses of Low Sugar Apple Juice</brief_title>
  <acronym>HB-RCT2-2015</acronym>
  <official_title>Double-blind, Randomized, Controlled, Four Treatment Four Period Cross-over Trial on Glycemic Response, Excretion of Gluconate and Tolerability of Two Doses of Low Sugar Apple Juice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center Kiel GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nofima</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center Kiel GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, double-blind, randomized controlled cross-over trial with four treatments and&#xD;
      four time points.&#xD;
&#xD;
      The study has three primary objectives. The first primary objective is to confirm the&#xD;
      reduction of postprandial glycemic and insulinemic response after consumption of 500 ml&#xD;
      glucose-free apple juice compared to 500 ml untreated apple juice as could be shown in a&#xD;
      previous study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, double-blind, randomized controlled cross-over trial with four treatments and&#xD;
      four time points.&#xD;
&#xD;
      The study has three primary objectives. The first primary objective is to confirm the in a&#xD;
      previous study shown reduction of postprandial glycemic and insulinemic response after&#xD;
      consumption of 500 ml glucose-free apple juice compared to 500 ml untreated apple juice.&#xD;
&#xD;
      The second primary objective is to show the reduction of postprandial glycemic response after&#xD;
      consumption of 250 ml glucose-free apple juice compared to 250 ml untreated apple juice.&#xD;
&#xD;
      The third primary objective is to show the reduction of insulinemic response after&#xD;
      consumption of 250 ml glucose-free apple juice compared to 250 ml untreated apple juice.&#xD;
&#xD;
      Secondary objectives include safety aspects, specifically the occurrence of diarrhoea in all&#xD;
      four treatment groups, differences between treatment groups on the Bristol Stool Forms Scale,&#xD;
      gastro-intestinal symptoms and laboratory parameters. In addition, gluconate excretion and&#xD;
      excreted portion of ingested gluconate are of interest as well as faecal pH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>a double-blind randomised controlled cross-over trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The test products (verum and control) are similar in flavour, color, texture, appearance and identical in packaging to ensure the double-blind, controlled design of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>iAUC glucose 500</measure>
    <time_frame>120 min after ingestion</time_frame>
    <description>Incremental AUC (iAUC120) of blood glucose levels (according to FAO/WHO) after 500 ml juice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>iAUC insulin 500</measure>
    <time_frame>120 min after ingestion</time_frame>
    <description>iAUC insulin 500</description>
  </primary_outcome>
  <primary_outcome>
    <measure>iAUC glucose 250</measure>
    <time_frame>120 min after ingestion</time_frame>
    <description>Incremental AUC (iAUC120) of blood glucose levels (according to FAO/WHO) after 250 ml juice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>iAUC insulin 250</measure>
    <time_frame>120 min after ingestion</time_frame>
    <description>iAUC insulin 250</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diarrhea</measure>
    <time_frame>before and 60 and 120 minutes after ingestion with respect to the last 2 hours</time_frame>
    <description>Occurrence of diarrhoea as assessed by stool frequency and Bristol Stool Forms Scale (Lewis, 1997) (3 or more loose or liquid stools per day, definition according to the WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastro-intestinal symptoms</measure>
    <time_frame>before and 60 and 120 minutes after ingestion with respect to the last 2 hours</time_frame>
    <description>Assessed by completing questionnaires on gastrointestinal symptoms (GSRS; Svedlund 1988; Dimenäs 1995; Revicki 1998)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>verum 500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control 500</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>verum 250</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control 250</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>500 ml glucose-depleted apple juice</intervention_name>
    <arm_group_label>verum 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>500 ml conventional apple juice</intervention_name>
    <arm_group_label>control 500</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>250 ml glucose-depleted apple juice</intervention_name>
    <arm_group_label>verum 250</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>250 ml conventional apple juice</intervention_name>
    <arm_group_label>control 250</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged ≥ 18y&#xD;
&#xD;
          2. Impaired fasting glucose (IFG)&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
          4. Consent to collect stools and urine four times for three days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects currently enrolled in another clinical study&#xD;
&#xD;
          2. Subjects having finished another clinical study within the last 4 weeks before&#xD;
             inclusion.&#xD;
&#xD;
          3. Subjects having participated in the study HB-RCT1-2015&#xD;
&#xD;
          4. Hypersensitivity, allergy or idiosyncratic reaction to apple, apple juice or other&#xD;
             apple containing food&#xD;
&#xD;
          5. Acute or chronic infections&#xD;
&#xD;
          6. Renal insufficiency&#xD;
&#xD;
          7. Gastrointestinal illness&#xD;
&#xD;
          8. No stools of type 5-7 of Bristol Stool Form Scale within the last week before&#xD;
             inclusion&#xD;
&#xD;
          9. History of gastrointestinal surgery&#xD;
&#xD;
         10. Known fructose intolerance&#xD;
&#xD;
         11. Overt diabetes mellitus&#xD;
&#xD;
         12. Endocrine disorders&#xD;
&#xD;
         13. Any disease or condition which might compromise significantly the hematopoietic,&#xD;
             renal, endocrine, pulmonary, hepatic, cardiovascular, immunological, central nervous,&#xD;
             dermatological or any other body system with the exception of the conditions defined&#xD;
             by the inclusion criteria&#xD;
&#xD;
         14. History of hepatitis B and C&#xD;
&#xD;
         15. History of HIV infection&#xD;
&#xD;
         16. History of coagulation disorders or pharmaceutical anti-coagulation (with the&#xD;
             exception of acetylsalicylic acid)&#xD;
&#xD;
         17. Regular medical treatment including OTC, which may have impact on the study aims (e.g.&#xD;
             gluconic acid-containing OTCs, antidiabetic drugs, laxatives etc.)&#xD;
&#xD;
         18. Major cognitive or psychiatric disorders&#xD;
&#xD;
         19. Subjects who are scheduled to undergo hospitalization during the study period&#xD;
&#xD;
         20. Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)&#xD;
&#xD;
         21. Present drug abuse or alcoholism&#xD;
&#xD;
         22. Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, Dr. (MD)</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRC Clinical Research Center Kiel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC Clinical Research Center Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycemic response, enzymatic conversion, gluconate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

